Publications by authors named "J Pourrat"

Objective: To describe characteristics and long-term outcomes of patients with microscopic polyangiitis (MPA), an antineutrophil cytoplasm antibody (ANCA)-associated small-vessel necrotizing vasculitis.

Methods: MPA patients from the French Vasculitis Study Group Registry satisfying the European Medicines Agency algorithm were analyzed retrospectively. Characteristics at diagnosis, treatments, relapses and deaths were analyzed to identify factors predictive of death or relapse.

View Article and Find Full Text PDF

Objective: Outcomes of systemic lupus erythematosus (SLE) and lupus nephritis (LN) are highly heterogeneous among some populations because of interactions between genetic, epigenetic, environmental, and socioeconomic factors. A better characterization of social and ethnic disparities in mixed populations may thus help to develop individualized treatment regimens.

Materials And Methods: Retrospective observational study including all patients with LN diagnosed between January 1993 and January 2014 in the only Nephrology Department of French Polynesia.

View Article and Find Full Text PDF

Monoclonal gammopathy of renal significance (MGRS) regroups renal disorders caused by a monoclonal immunoglobulin without overt hematological malignancy. MGRS includes tubular disorders, glomerular disorders with organized deposits, and glomerular disorders with non-organized deposits, such as proliferative glomerulonephritis with monoclonal IgG deposits. Since glomerular involvement related to monotypic IgA deposits is poorly described we performed retrospective analysis and defined clinico-biological characteristics, renal pathology, and outcome in 19 referred patients.

View Article and Find Full Text PDF

The overall and renal outcomes of patients with Goodpasture syndrome (GS), a rare autoimmune disorder characterized by circulating anti-GBM antibodies and rapidly progressive glomerulonephritis and/or pulmonary hemorrhage, have mostly been reported in small-sized cohorts or by aggregating patients receiving a variety of therapies that include aggressive (i.e., combined plasma exchanges, corticosteroids, and cyclophosphamide) and less aggressive (i.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to explore how genetic variations (polymorphisms) in specific enzymes (GST and CYP) affect kidney outcomes and adverse drug reactions in lupus nephritis patients treated with cyclophosphamide (CYC).
  • - Involving 70 patients, it found that certain genetic profiles, especially the GSTP1 variant, were linked to poorer kidney outcomes, while the GSTM1 null genotype was tied to a higher risk of adverse reactions.
  • - The results highlight that GST genetic polymorphisms significantly influence kidney health and medication side effects in lupus nephritis treatment, while cytochrome P450 variations showed no significant impact.
View Article and Find Full Text PDF